Navigation Links
Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer
Date:7/29/2014

OXFORD, England, July 29, 2014 /PRNewswire/ --

 

Glide Pharmaceutical Technologies Ltd (Glide Pharma) today announced that it has taken an exclusive worldwide licence to an innovative prostate cancer diagnostic technology from FScan Ltd, a Durham University spin-out company.  Under the terms of the agreement, Glide Pharma will pay an upfront fee, development and commercial milestone payments, and royalties on future product sales.  Glide Pharma has also taken an option for additional exclusive licences to FScan diagnostic technologies, for use in other conditions.  

The licensed technology pioneers the use of lanthanide complexes for the non-invasive, rapid and accurate measurement of citrate levels in seminal fluid.  The link between citrate levels and prostate cancer is well documented, providing the opportunity to develop an effective diagnostic test.  Further clinical validation of this approach is currently underway in studies co-ordinated by Professor Mark Emberton, Consultant Urologist at University College London.

The current routinely-used prostate-specific antigen (PSA) diagnostic has major limitations, with inaccurate results leading to large numbers of patients undergoing unnecessary additional testing and biopsy.  A rapid, accurate, non-invasive test would meet a major unmet clinical need, and consequently has significant commercial potential.  Estimates suggest that approximately 24 million PSA tests are conducted each year in the US alone, with the worldwide market valued at more than $2 billion.  

Glide Pharma plans to provide the technology initially as an analyte specific reagent in the USA.  In the longer-term, the company intends to develop a prostate cancer diagnostic test, and to pursue regulatory approval in the US and Europe.

"Licensing this novel diagnostic technology is an important strategic step for Glide as it broadens both our pipeline and technology base, offers the potential of early revenues, and longer-term plays to our strengths in device development and scale-up," said Dr Mark Carnegie-Brown, Glide Pharma's CEO.  "We believe this innovative technology has the potential to revolutionise the prostate cancer diagnostic market, where there is a clear need for an accurate, rapid non-invasive test.  With our existing portfolio of therapeutics and vaccines making excellent progress, we plan to accelerate the development of this potentially important diagnostic alongside our lead programmes."

Kish Mistry, FScan's CEO, commented, "We are delighted to have executed this agreement with Glide Pharma as they are very well positioned to move this promising technology forward for the benefit of clinicians and patients in the prostate cancer field."

About Glide Pharma 

Glide Pharma is a pharmaceutical development and device company.  Its lead products are based on its proprietary solid dose injector, the Glide SDI®, which offers the potential of improved compliance in long-term therapy and enhanced immune responses to vaccines.  Glide's pipeline includes octreotide, parathyroid hormone and anthrax and influenza vaccines.

The company has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors.  Glide Pharma has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.  For more information please visit http://www.glidepharma.com.

Contacts
Dr Mark Carnegie-Brown
Chief Executive
Glide Pharma
Tel: +44(0)1235-577120

Richard Bungay
Chief Financial Officer
Glide Pharma
Tel: +44(0)1235-577120

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241


'/>"/>
SOURCE Glide Pharma
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
2. TriReme Medical and Japanese Partner Century Medical, Inc., Receive Shonin Approval for GliderXtreme PTA Catheter in Japan
3. Glide Pharma Completes £14.0 Million ($21.4 Million) Fundraising for Scale Up of Drug and Device Manufacturing Processes and Product Development
4. Verathon, maker of GlideScope video laryngoscopes, provides free educational DVD to promote best practices in pediatric airway management.
5. TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter
6. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
7. Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
8. Portugal Pharmaceuticals and Healthcare Report Q3 2014
9. Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2014 On August 12, 2014
10. Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427
11. ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017  Genesis Healthcare Services has merged with ... made by Bill Monast , President and CEO ... Nathan Feltman , executives with Home Health Depot, ... This acquisition helps Hospice Cloud maintain ... enabled durable medical equipment (DME) solutions for the hospice ...
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis ... the global Fibromyalgia market. The research answers the following ... for Fibromyalgia and their clinical attributes? How are they positioned in ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the ... Market (ILTM) show in Cannes (France), XO Private has initiated a second print-run of ... book measures almost a metre across when open, weighs in at more than six ...
(Date:2/24/2017)... , ... February 24, 2017 , ... In the Health ... be a top priority because it’s not if you will be attacked, but when.” ... when it comes to digital health care. , Improvements in auditing and monitoring have ...
(Date:2/24/2017)... Diego, CA (PRWEB) , ... February 24, 2017 , ... ... its 2017 national conference convening academic faculty engaged in or interested in palliative care ... and Research,” will be held in North County San Diego on Sept. 28 ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, ... thought leadership , media relations, social media, content marketing and SEO, is ... powered through Act-On, an intuitive marketing automation platform. , Rosica will now offer ...
(Date:2/23/2017)... ... 2017 , ... The 89th Academy Awards will be celebrated this weekend, which ... Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to ... the Center for American Progress (CAP), for its report, Lessons From State Performance on ...
Breaking Medicine News(10 mins):